Low molecular weight heparin as adjuvant therapy in active ulcerative colitis.
about
Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitisUnfractionated or low-molecular weight heparin for induction of remission in ulcerative colitisUnfractionated or low-molecular weight heparin for induction of remission in ulcerative colitisInflammatory bowel disease and thrombosisAnticoagulation therapy in cerebral sinovenous thrombosis and ulcerative colitis in childrenReview article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease.New developments in the treatment of inflammatory bowel disease.Tissue factor-dependent chemokine production aggravates experimental colitis.Key role of mast cells and their major secretory products in inflammatory bowel disease.Non-Anticoagulant Fractions of Enoxaparin Suppress Inflammatory Cytokine Release from Peripheral Blood Mononuclear Cells of Allergic Asthmatic Individuals.Drug treatment of ulcerative colitis: unfractionated heparin, low molecular weight heparins and beyond.Orally Administered Enoxaparin Ameliorates Acute Colitis by Reducing Macrophage-Associated Inflammatory ResponsesThe vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology.Inhibitory effect of heparin-derived oligosaccharides on secretion of interleukin-4 and interleukin-5 from human peripheral blood T lymphocytes.Cerebral sinus thrombosis in patients with inflammatory bowel disease: a case report.Therapy insight: Vascular complications in patients with inflammatory bowel disease.Effects of low molecular weight heparin on platelet surface P-selectin expression and serum interleukin-8 production in rats with trinitrobenzene sulphonic acid-induced colitis.Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammationMedical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials.Thrombosis and inflammatory bowel disease: a call for improved awareness and prevention.The multivalent activity of the tissue factor-thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention.Unfractionated or low molecular weight heparin for induction of remission in ulcerative colitis: a Cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials.Heparan sulfate inhibitors and their therapeutic implications in inflammatory illnesses.Heparins in ulcerative colitis: proposed mechanisms of action and potential reasons for inconsistent clinical outcomes.Medical application of glycosaminoglycans: a review.Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis.Hyperhomocysteinemia and inflammatory bowel disease: prevalence and predictors in a cross-sectional study.Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial.Efficacy of low molecular weight heparin in patients with acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support.Nanoparticle-based delivery enhances anti-inflammatory effect of low molecular weight heparin in experimental ulcerative colitis.Randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis.Low-molecular-weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study.Massive haemorrhage induced by low molecular weight heparin in a patient with steroid refractory ulcerative colitis.Therapeutic Potential of Enoxaparin in Lichen Planus: Exploring Reasons for Inconsistent Reports.
P2860
Q24188013-0C0EF02C-4B7B-440E-ACEE-313BFB4E1005Q24234403-CA120FB0-19EE-4CA5-9E34-7D892317CAB8Q24243052-945A1ADE-CC41-4A9E-BEA7-900063E5AC63Q26830337-C6B148CB-2289-462E-B848-A91DFDD279A4Q28193814-ADF69E16-F144-413E-A2B6-A1A71AA8C0E8Q34078523-2C899526-E0D2-4FBF-B6E6-B7A78C28CA84Q34544666-74341B0D-D30E-47E6-AF9D-DC4C29484988Q35287011-89F8E6F1-90F6-4829-9E13-1B4D86D9DBB4Q35648042-B923A86A-DE7B-47DC-BA99-1B6128824423Q35653704-CEBEBD57-B3D3-4E38-A01C-6D5BE66A397CQ35680595-B29317BF-429A-48E2-BFCD-004C886FD12EQ35719599-413083BD-378B-485B-8092-F2476B563C0CQ36056593-C62A8B5F-7A6F-4B86-BB52-3FA83AC180B8Q36076384-4082ABA8-41C5-4DF8-99B4-4ADC544233ADQ36214032-E28DCAE9-99E0-44FF-BC70-D68F0CF68070Q36304138-E2253261-320F-4D5C-AC9E-ED2E73FF647EQ36474174-4CF9D161-69AF-4834-9B18-C4BA4D19598FQ36503343-776143B8-3DA1-4896-8BD3-2C30CAD269C2Q36609208-9E402120-34A5-4695-9572-372FE6F9CA40Q37789688-8CAC206A-901F-4CC5-AA84-A35E7C6A7DD9Q37808230-23044EB8-C18E-4715-A19E-DE787D68347FQ37880700-6856909D-13C0-43DE-818C-27CB552D0AF4Q38116039-AADB7B22-EF4A-45A4-B860-CB4542070A82Q38574126-AB076138-E02D-4A66-B97F-F2F8BF74DCEFQ39083233-1A3E893C-6489-4DB8-AC92-764EB3813532Q40536084-F7DF7638-D78B-42E3-942A-A7BA980A7220Q43684198-C791B479-0941-402C-8B1A-CFD81B47C9B6Q44364956-F2A5C1DE-BD62-4296-A55B-24D7CAD5ABD4Q45156975-6DC1BA7B-2539-4630-9F60-CAD3E0B1354CQ47212964-B8F64F0B-6010-46B8-A5E5-899BB3BDADAEQ47303858-568FA7CF-FAC8-4D64-9DC4-F4DB6BC67BD0Q47339211-FD459336-6467-4726-B278-BF1677408F2EQ47415352-A52AE7A3-277B-4359-A959-9523E89FAF47Q55262670-78B3A7F3-F8B1-4A47-A5FB-D2FD01A85920
P2860
Low molecular weight heparin as adjuvant therapy in active ulcerative colitis.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Low molecular weight heparin as adjuvant therapy in active ulcerative colitis.
@en
Low molecular weight heparin as adjuvant therapy in active ulcerative colitis.
@nl
type
label
Low molecular weight heparin as adjuvant therapy in active ulcerative colitis.
@en
Low molecular weight heparin as adjuvant therapy in active ulcerative colitis.
@nl
prefLabel
Low molecular weight heparin as adjuvant therapy in active ulcerative colitis.
@en
Low molecular weight heparin as adjuvant therapy in active ulcerative colitis.
@nl
P2093
P2860
P1476
Low molecular weight heparin as adjuvant therapy in active ulcerative colitis.
@en
P2093
Sjöqvist U
Törkvist L
P2860
P304
P356
10.1046/J.1365-2036.1999.00599.X
P407
P577
1999-10-01T00:00:00Z